ATE392210T1 - Methoden zur behandlung von festen tumoren und metastasen mit gentherapie - Google Patents

Methoden zur behandlung von festen tumoren und metastasen mit gentherapie

Info

Publication number
ATE392210T1
ATE392210T1 AT00968760T AT00968760T ATE392210T1 AT E392210 T1 ATE392210 T1 AT E392210T1 AT 00968760 T AT00968760 T AT 00968760T AT 00968760 T AT00968760 T AT 00968760T AT E392210 T1 ATE392210 T1 AT E392210T1
Authority
AT
Austria
Prior art keywords
gene therapy
metastasis
methods
solid tumors
treating solid
Prior art date
Application number
AT00968760T
Other languages
English (en)
Inventor
Carlos Aguilar-Cordova
Original Assignee
Aguilar Cordova Carlos Estuard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aguilar Cordova Carlos Estuard filed Critical Aguilar Cordova Carlos Estuard
Application granted granted Critical
Publication of ATE392210T1 publication Critical patent/ATE392210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00968760T 1999-10-07 2000-10-07 Methoden zur behandlung von festen tumoren und metastasen mit gentherapie ATE392210T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15806899P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
ATE392210T1 true ATE392210T1 (de) 2008-05-15

Family

ID=22566564

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968760T ATE392210T1 (de) 1999-10-07 2000-10-07 Methoden zur behandlung von festen tumoren und metastasen mit gentherapie

Country Status (7)

Country Link
EP (1) EP1223952B1 (de)
JP (2) JP5557974B2 (de)
AT (1) ATE392210T1 (de)
AU (1) AU7862600A (de)
CA (1) CA2386374A1 (de)
DE (1) DE60038624T2 (de)
WO (1) WO2001024684A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
AU2003247094A1 (en) * 2002-07-19 2004-02-09 Ludwig Institute For Cancer Research Enhancing the effect of radioimmunotherapy in the treatment of tumors
ATE458500T1 (de) 2003-11-14 2010-03-15 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
JP4560629B2 (ja) * 2005-03-31 2010-10-13 国立大学法人 筑波大学 腫瘍壊死誘導療法の抗腫瘍効果増強剤
EP2793893A4 (de) 2011-11-23 2015-07-08 Intellikine Llc Verbesserte behandlungspläne unter verwendung von mtor-inhibitoren
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
CN116196427A (zh) 2015-10-21 2023-06-02 泰克利森有限公司 用于免疫介导的癌症疗法的组合物和方法
EP3205356A1 (de) * 2016-02-10 2017-08-16 Onkoloski Institut Ljubljana Plasmidexpressionsvektor zur codierung von humanem interleukin 12 unter transkriptionskontrolle von p21-promotor und ohne antibiotikaresistenz für krebsgentherapie und andere verwendungen davon
EP3810109A4 (de) 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. Zusammensetzungen und verfahren zur hemmung von cd73
CN112955130A (zh) 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
BR112022023199A2 (pt) 2020-05-15 2023-04-04 Algen Biotechnologies Inc Certas composições químicas e métodos de uso das mesmas
BR112022025512A2 (pt) * 2020-06-15 2023-01-17 Kortuc Inc Sensibilizador para tratamento de câncer
KR102570785B1 (ko) * 2021-05-06 2023-08-24 연세대학교 산학협력단 화학방사선요법에 대한 정보 제공 방법 및 이를 적용한 디바이스

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1993002556A1 (en) * 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
AU742365B2 (en) * 1997-03-14 2002-01-03 Selective Genetics, Inc. Adenoviral vectors with modified tropism
AU2656299A (en) * 1998-02-03 1999-08-16 Baylor College Of Medicine Synergism between thymidine kinase gene therapy and topoisomerase i and topoisomerase ii inhibitors

Also Published As

Publication number Publication date
JP2003528813A (ja) 2003-09-30
WO2001024684A3 (en) 2001-10-25
EP1223952A4 (de) 2004-12-08
JP5557974B2 (ja) 2014-07-23
AU7862600A (en) 2001-05-10
WO2001024684A2 (en) 2001-04-12
CA2386374A1 (en) 2001-04-12
JP2012001566A (ja) 2012-01-05
EP1223952B1 (de) 2008-04-16
EP1223952A2 (de) 2002-07-24
DE60038624D1 (de) 2008-05-29
DE60038624T2 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
ATE392210T1 (de) Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
HK1101348A1 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
DK1165108T3 (da) Anvendelse af et ekstrakt af Serenoa repens til fremstilling af et lægemiddel til behandling af prostatacancer
NO20000752D0 (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
WO1999051263A3 (en) Methods and modified cells for the treatment of cancer
NO20002412L (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
UA88294C2 (ru) ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
DE60212415D1 (de) Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
ATE296663T1 (de) Vorrichtung zur behandlung von tumoren
FitzGerald et al. Prostate carcinoma: opportunities for translational research
ATE291620T1 (de) Mammakarzinom-assoziiertes gen
GB0207251D0 (en) Lymphoma-associated antigens
CY1116323T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ TNFα-ΣΧΕΤΙΖΟΜΕΝΩΝ ΔΙΑΤΑΡΑΧΩΝ
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
WO2001028573A3 (en) Monocyte conditioned medium for cancer treatment
UA40084A (uk) Спосіб лікування занедбаних форм раку молочної залози без наявності віддалених метастазів
AU2013204147B2 (en) Treatment of TNFalpha related disorders
UA30998A (uk) Спосіб комплексного лікування раку яєчників

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties